Results 191 to 200 of about 1,251,059 (351)

Developing the Medical Oncology Treatment Plan and Summary [PDF]

, 2006

openalex   +1 more source

Supplementum 283: Abstracts of the Swiss Oncology & Hematology Congress (SOHC)

Swiss Medical Weekly
Swiss Society of Medical Oncology, Swiss Society of Hematology, Swiss Group for Clinical Cancer Research   +2 more
doaj   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology. [PDF]

Front Med (Lausanne)
Bongurala AR, Save D, Virmani A.
europepmc   +1 more source

Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department. [PDF]

Transl Lung Cancer Res, 2023
Sánchez JC, Nuñez-García B, Ruano-Ravina A, Blanco M, Martín-Vegue AR, Royuela A, Cantos B, Méndez M, Calvo V, Provencio M.   +9 more
europepmc   +1 more source

Importance of three-dimensional treatment planning and dose-volume histogram analysis in the performance and evaluation of intravascular brachytherapy Louis B. Harrison, Akiko Maehara, Neil S. Patel, Neil J. Weissman, Ron Waksman, Gary S. Mintz, Taya L. McMillan, Julianna Pisch, Harry Quon, Nathan Yang, Rosanna Chan, Huchen Xie, Sou-Tung Chiu-Tsao. Department of Radiation Oncology, Beth Israel Medical Center & St. Luke's-Roosevelt Hospital Center, New York, NY, Cardiovascular Research …

, 2001

openalex   +1 more source

Referral to Medical Oncology: A Crucial Step in the Treatment of Older Patients with Stage III Colon Cancer [PDF]

, 2006
RuiLi Luo, Sharon H. Giordano, Jean L. Freeman, Dong Zhang, James S. Goodwin   +4 more
openalex   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Pharmacogenomics and Big Data in medical oncology: developments and challenges. [PDF]

Ther Adv Med Oncol
Marcu LG, Marcu DC.
europepmc   +1 more source

Application of a cost calculation approach in medical oncology: case of Hassan II university hospital in Morocco. [PDF]

Cost Eff Resour Alloc, 2023
Benabdallah A, Jellouli T.
europepmc   +1 more source